Samyang, Access Pharmaceuticals Ink RNAi-Delivery Research Deals

The deals suggest that big pharma remains interested in the gene-silencing technology despite recent pullbacks in the sector, which have raised concerns among industry watchers.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.